NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Sees Large Drop in Short Interest

NeuBase Therapeutics, Inc. (NASDAQ:NBSE) saw a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 24,500 shares, a drop of 83.6% from the March 31st total of 149,100 shares. Approximately 0.8% of the company’s stock are short sold. Based on an average daily volume of 230,400 shares, the short-interest ratio is currently 0.1 days.

NeuBase Therapeutics Stock Up 5.0 %

Shares of NBSE traded up $0.02 during mid-day trading on Thursday, reaching $0.44. 25,441 shares of the stock traded hands, compared to its average volume of 202,576. The firm has a market cap of $1.66 million, a price-to-earnings ratio of -0.06 and a beta of 0.83. The stock has a fifty day simple moving average of $0.68 and a 200 day simple moving average of $0.70. NeuBase Therapeutics has a 12-month low of $0.39 and a 12-month high of $4.80.

NeuBase Therapeutics Company Profile

NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.